FDA Approves NVCR Cancer Device; RGNX Receives CRL; ONCO Acquires XBOT; PHIO PH-762 Advances

The U.S. Food and Drug Administration (FDA) approved NVCR (NASDAQ:NVCR)’s cancer detection device, expanding its market access. Ridge Regression Neuroscience (NASDAQ:RGNX) received a Complete Response Letter (CRL) with a request for additional data, delaying potential approvals. Onco Health (NASDAQ:ONCO) announced the acquisition of XBOT, a robotic surgical platform, to bolster its oncology product portfolio. Pharmaceutical company PHIO (NASDAQ:PHIO) reported that PH-762, a phase 2 cancer treatment, is maintaining its pace in clinical trials, signaling continued enrollment and data collection.